EricaLMayerMD

Oncology • Boston, MA

Assistant Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Mayer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mayer's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-3800

Fax+1 617-632-1930

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006
Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000

Certifications & Licensure

MA State Medical License 2002 - 2025
NH State Medical License 2024 - 2024
American Board of Internal Medicine Medical Oncology

Clinical Trials

ZD6474 (Zactima) and Metronomic Chemotherapy in Advanced Breast Cancer Start of enrollment: 2007 Jul 01
Completed
Phase 1
Hypertension in Breast Cancer Patients Receiving Bevacizumab Start of enrollment: 2008 Jan 01
Terminated
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Eribulin in HER2 Negative Metastatic BrCa Start of enrollment: 2013 May 01
Completed
Phase 2
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Cisplatin vs Paclitaxel for Triple Negative Breast Cancer Start of enrollment: 2014 Apr 01
Completed
Phase 2
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer Start of enrollment: 2014 Jan 01
Completed
Phase 2
Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Start of enrollment: 2015 Jun 01
Terminated
Phase 1, Phase 2
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Active, not recruiting
Phase 3
Palbociclib After CDK and Endocrine Therapy (PACE) Start of enrollment: 2017 Sep 05
Active, not recruiting
Phase 2
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer Start of enrollment: 2020 Dec 18
Recruiting
Phase 2
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer Start of enrollment: 2023 Oct 05
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

164 citations
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
Panagiotis A. Konstantinopoulos, William T. Barry, Michael J. Birrer, Shannon N. Westin, Karen Cadoo
The Lancet. Oncology. 2019-04-01
27 citations
Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer.
Felipe Batalini, Niya Xiong, Nabihah Tayob, Madeline Polak, Julia Eismann
Clinical Cancer Research. 2022-04-14
129 citations
Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update.
Fabrice Andre, Nofisat Ismaila, Kimberly H Allison, William E Barlow, Deborah E Collyar
Journal of Clinical Oncology. 2022-06-01

Lectures

TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBCâ€”Evaluating the homologous recombination deficiency (HRD) biomarker.
2019 ASCO Annual Meeting - 6/1/2019
Palbociclib after CDK and endocrine therapy (PACE): A randomized phase II study of fulvestrant, palbociclib, and avelumab for endocrine pre-treated ER+/HER2- metastati...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Cracking the Code: Predicting Late Risk in Hormone-Receptor-Positive Disease
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast CancerJuly 9th, 2024
Optimizing Treatment for Older Patients with HR+ Low-Risk Breast CancerJanuary 5th, 2023
No Benefit of Palbociclib with Fulvestrant Beyond Progression on Prior CDK4/6 InhibitionDecember 20th, 2022
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member